This technology employs AAV gene targeting to disrupt the Caspase-3 genomic locus in HCT116 colon cancer cells, generating caspase-3 null cell lines. Two distinct clones have been developed and thoroughly characterized, demonstrating features such as complete deletion of both alleles and enhanced sensitivity to specific anticancer agents. These cell lines serve as precise tools to investigate apoptosis and cell death signaling pathways, offering researchers a reliable in vitro model for studying the fundamental mechanisms underlying programmed cell death in cancer.
Description
What distinguishes this approach is its novel ability to produce the first known caspase-3 deficient human cells, setting it apart from traditional models that rely on partial or conditional suppression. The use of AAV gene targeting ensures specific and efficient disruption, yielding consistent results across clones. Additionally, the increased responsiveness to therapeutic agents highlights its potential in uncovering alternate cell death mechanisms and informing future cancer therapy strategies, making this an invaluable asset in the pursuit of understanding and overcoming treatment resistance.
Applications
- Anticancer drug screening
- Apoptosis signaling research
- Targeted therapy evaluation
- Cancer cell death analysis
Advantages
- Provides a unique, validated in vitro model for studying apoptosis and caspase-3 function in human cancer cells.
- Enhances sensitivity to selective anticancer agents, offering a potential tool to explore alternative cell death pathways.
- Represents the first caspase-3 knockout human cell line, filling a critical gap in cancer research models.
- Established using AAV gene targeting technology, ensuring precise genetic deletion and reliability for experimental studies.
IP Status
Research Tool
